Cerebral paragonimiasis represents an uncommon but serious presentation in which the parasite migrates to the central nervous system, requiring a treatment approach tailored to this specific site of involvement.
This protocol addresses patients with cerebral paragonimiasis — involvement of the brain or central nervous system. The cerebral location introduces additional management considerations beyond standard pulmonary disease, because the dying parasite can provoke a significant local inflammatory response within the CNS.
Management centres on oral anti-parasitic therapy with praziquantel. In the cerebral setting, this is combined with a course of corticosteroids to reduce the inflammatory response around dying flukes — a key consideration that distinguishes this presentation from uncomplicated pulmonary paragonimiasis.